DK0759067T3 - Transformerende vækstfaktor alfa-H1 - Google Patents

Transformerende vækstfaktor alfa-H1

Info

Publication number
DK0759067T3
DK0759067T3 DK94916791T DK94916791T DK0759067T3 DK 0759067 T3 DK0759067 T3 DK 0759067T3 DK 94916791 T DK94916791 T DK 94916791T DK 94916791 T DK94916791 T DK 94916791T DK 0759067 T3 DK0759067 T3 DK 0759067T3
Authority
DK
Denmark
Prior art keywords
alpha
polypeptide
growth factor
transforming growth
factor alpha
Prior art date
Application number
DK94916791T
Other languages
Danish (da)
English (en)
Inventor
Paul S Meissner
Rebecca Fuldner
Mark D Adams
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of DK0759067T3 publication Critical patent/DK0759067T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94916791T 1994-03-08 1994-05-12 Transformerende vækstfaktor alfa-H1 DK0759067T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/208,008 US5633147A (en) 1994-03-08 1994-03-08 Transforming growth factor αH1
PCT/US1994/005476 WO1995024466A1 (en) 1994-03-08 1994-05-12 Transforming growth factor alpha h1

Publications (1)

Publication Number Publication Date
DK0759067T3 true DK0759067T3 (da) 2001-10-22

Family

ID=22772852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94916791T DK0759067T3 (da) 1994-03-08 1994-05-12 Transformerende vækstfaktor alfa-H1

Country Status (14)

Country Link
US (1) US5633147A (zh)
EP (2) EP1063293A3 (zh)
JP (1) JPH09509846A (zh)
KR (1) KR970701776A (zh)
CN (1) CN1087344C (zh)
AT (1) ATE205254T1 (zh)
AU (1) AU681406B2 (zh)
CA (1) CA2184583A1 (zh)
DE (1) DE69428214T2 (zh)
DK (1) DK0759067T3 (zh)
ES (1) ES2161246T3 (zh)
PT (1) PT759067E (zh)
WO (1) WO1995024466A1 (zh)
ZA (1) ZA943465B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US20020188110A1 (en) * 1994-03-08 2002-12-12 Human Genome Sciences, Inc. Transforming growth factor alpha HI
US6074839A (en) * 1994-03-08 2000-06-13 Human Genome Sciences, Inc. Transforming growth factor αHI
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
ATE309360T1 (de) * 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6410506B1 (en) 1995-05-19 2002-06-25 Human Genome Sciences, Inc. Transforming growth factor α HII
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7294482B2 (en) * 1998-11-19 2007-11-13 Millennium Pharmaceuticals, Inc. EGF-like nucleic acids
WO2000029438A1 (en) * 1998-11-19 2000-05-25 Millennium Pharmaceuticals, Inc. Egf-like nucleic acids and polypeptides and uses thereof
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US20020099008A1 (en) * 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
ATE364315T1 (de) * 1999-04-26 2007-07-15 Applied Protein Sciences Llc Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
WO2001012127A2 (en) * 1999-08-19 2001-02-22 Stem Cell Pharmaceuticals, Inc. TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
CA2407910C (en) 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys
NZ518077A (en) * 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
WO2002083704A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2004089357A2 (en) * 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
KR101622412B1 (ko) * 2007-10-19 2016-05-18 제넨테크, 인크. 시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI890312A (fi) * 1988-01-25 1989-07-26 Oncogen Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein.
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein

Also Published As

Publication number Publication date
EP1063293A2 (en) 2000-12-27
EP0759067A1 (en) 1997-02-26
PT759067E (pt) 2002-02-28
EP1063293A3 (en) 2001-07-11
DE69428214D1 (de) 2001-10-11
JPH09509846A (ja) 1997-10-07
WO1995024466A1 (en) 1995-09-14
EP0759067B1 (en) 2001-09-05
EP0759067A4 (en) 1997-10-22
AU681406B2 (en) 1997-08-28
ZA943465B (en) 1995-11-20
ATE205254T1 (de) 2001-09-15
US5633147A (en) 1997-05-27
DE69428214T2 (de) 2002-06-27
KR970701776A (ko) 1997-04-12
CA2184583A1 (en) 1995-09-14
ES2161246T3 (es) 2001-12-01
CN1087344C (zh) 2002-07-10
CN1143386A (zh) 1997-02-19
AU6835094A (en) 1995-09-25

Similar Documents

Publication Publication Date Title
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
DK0751992T3 (da) Karendotelvækstfaktor 2
HUP0103758A2 (hu) Neurotróf faktorok
DE69333802T8 (de) Äusseres membranprotein von haemophilus
ATE277078T1 (de) N-terminal modifizierte polypeptide, und herstellungsprozess
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
DK1165791T3 (da) Humant cytokin som zalpha-receptor-ligand og anvendelse deraf
EP0787802A3 (zh)
AU4230493A (en) Diphtheria toxin receptor-binding region
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
EP0825996A4 (en) FACTOR-1 (FHF-1) HOMOLOGATED FIBROBLAST GROWTH FACTOR AND METHODS OF USE
ATE306549T1 (de) C-c ckr-1, ein c-c chemokin rezeptor
PT804562E (pt) Factor 2 de crescimento de tecido conjuntivo
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
EP0780472A3 (en) Stress proteins
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
ATE95422T1 (de) Ein synthetisches nonapeptid zur verwendung als adjuvant.
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
AU7144787A (en) Tumor-associated antigen (mol wt 68,000-48000; 40,000-80000; 28000-32000; 16000-19000)
WO2001075008A3 (fr) Nouveau polypeptide, protéine hélicase-anneau-hélicase 11, et polynucleotide codant pour ce polypeptide
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide